PRGN-3007 is under clinical development by Precigen and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I drugs for Hematological Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PRGN-3007 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRGN-3007 overview

PRGN-3007 is under development for the treatment of ROR1 positive hematological, solid tumors, relapsed refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphocytic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), b-cell acute lymphocytic leukemia (b-cell acute lymphoblastic leukemia) and triple negative breast cancer. It is administered through parenteral route. The drug candidate comprises of autologous T-cells modified by using a non-viral vector to express a chimeric antigen receptor (CAR) acts by targeting receptor tyrosine kinase-like orphan receptor 1-positive (ROR1) and PD-1 . It also expresses IL15 for the stability of CART cells. The therapeutic candidate is being developed based on UltraCAR-T technology.

Precigen overview

Precigen is a clinical-stage biotechnology company that discovers, develops and commercializes next-generation gene and cell therapies to target diseases in immuno-oncology, autoimmune disorders and infections. The company’s clinical pipeline includes AG019, PRGN-3005, PRGN-3006, PRGN-3007, PRGN-2009 and PRGN-2012 for the indications of type 1 diabetes, ovarian cancer, acute myeloid leukemia and myelodysplastic syndromes, hematological and solid tumors, recurrent respiratory papillomatosis. Precigen preclinical pipeline includes PRGN-5001, PRGN-2010, PRGN-2011, PRGN-2013 and AG017, among others for solid tumors and celiac disease. The company utilizes therapeutic platforms including UltraCAR-T, AdenoVerse therapies, ActoBiotics, multifunctional therapeutics, UltraVector, AdenoVerse, AttSite, UltraPorator and RheoSwitch, among others. The company operates in the US and Belgium. Precigen is headquartered in Germantown, Maryland, the US.

For a complete picture of PRGN-3007’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.